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ABSTRACT
Objectives: New data suggest that glioma stem-like cells (GSCs) and neural stem/progenitor cells
(NSCs) may share common origins. GSCs drive tumor proliferation and appear to be resistant to
classic chemotherapy, while the effects of chemotherapy on NSCs are not well studied. As the
role of NSCs in learning and memory is increasingly recognized, we need to identify drugs that
reduce neurotoxicity but are still effective against glial tumors.
Methods: We treated 3 human NSC cultures and multiple low- and high-grade GSC cultures with
the commonly used agents temozolomide (TMZ) and cisplatin (CIS), and with 2 newer, promising
drugs: the proteasome inhibitor bortezomib (BTZ) and the epidermal growth factor receptor ty-
rosine kinase inhibitor erlotinib (ERL). We measured cell survival, proliferation, cell death induc-
tion, and drug resistance markers.
Results: TMZ decreased NSC viability, while minimally affecting GSCs. TMZ induced NSC death,
which was partially compensated for by increased proliferation. CIS had similar effects. The
NSC’s sensitivity to TMZ and CIS correlated with low expression of the multidrug resistance gene
ABCG2, but not of MGMT or MSH1/MLH2. BTZ caused an 80% decrease in GSCs, while mini-
mally affecting NSCs. GSCs had lower proteasome levels and activity after BTZ treatment. ERL
treatment also decreased GSC numbers, but not NSC viability, which correlated with low EGFR
expression in NSCs compared to GSCs.
Conclusions: Newer chemotherapy agents ERL and BTZ are effective against GSCs yet produce
minimal effects on NSCs, while the older drugs TMZ and CIS are more toxic for NSCs than for
GSCs. The identification and testing of more selective drugs is clearly warranted. Neurology®
2011;76:1126–1134
GLOSSARY
BTZ  bortezomib; CIS  cisplatin; ERL  erlotinib; GSC  glioma stem-like cell; MGMT  methyl-guanine methyl trans-
ferase; NSC neural stem/progenitor cell; TMZ temozolomide.
In the United States, 22,000 people per year are diagnosed with primary brain tumors.1 Their
quality of life is diminished by treatment-induced deficits of learning and memory,2–4 mani-
fested across cognitive domains. Such deficits occur in patients with systemic malignancies who
receive chemotherapy but not brain radiation.5
Various agents are used to treat brain tumors. Temozolomide (TMZ), a commonly used
neuro-oncology drug, and cisplatin (CIS), a second-line glioma treatment, achieve high con-
centrations in the brain.6,7 TMZ is a DNA-alkylating agent, whereas CIS forms platinumDNA
adducts. TMZ resistance is due to high methyl-guanine methyl transferase (MGMT) levels.8
Resistance to CIS relates to inactivation of mismatch repair enzymes MLH1 and MSH29 and
overexpression of multidrug resistance proteins, especially ABCG2.10 Two additional classes,
epidermal growth factor receptor tyrosine kinase inhibitors (erlotinib [ERL])11,12 and the
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proteasome inhibitors (bortezomib [BTZ]),13
have passed preclinical testing,14,15 and showed
results in small studies.
Stem cell populations are important for both
tumor behavior and cognition. A subpopulation
of glioblastoma cells—the glioma stem-like cells
(GSCs)16—are positive for neural stem/progeni-
tor cells (NSCs) markers.17,18 GSCs are resistant
to radiation,19 and to TMZ, carboplatin, pacli-
taxel, and etoposide,20 but their sensitivity to
ERL or BTZ relative to non-GSC tumor com-
ponents or the NSCs is not yet described. By
contrast, NSCs persist throughout adulthood.21
Neurogenesis is important for learning22 and
memory.23 Radiation,24 and carmustine, CIS,
and 5-fluorouracil, are toxic to rat NSCs.25 The
effects of chemotherapy on human NSCs are
unknown.
METHODS Standard protocol approvals, registra-
tions, and patient consents. IRB approval was obtained at
University of California Irvine Medical Center and Children’s
Hospital of Orange County.
Isolation and expansion of cells. NSCs (SC23, SC27,
SC30) were derived from brains of premature neonates and cul-
tured as previously described.26 HuTuP01 glioblastoma multi-
forme GSCs were a gift from Dr. David Panchision (Children’s
National Medical Center),27 and the stable tumor cell lines
D54-MG and U251 were gifts from Dr. Darrell Bigner (Duke).
Fresh brain tumors (low- and high-grade) were taken at surgery
and dissociated, with neuropathologic review completed by a
specialty neuropathologist (table e-1 on the Neurology® Web site
at www.neurology.org). Cells were cultured on matrigel-coated
dishes in 1:1 DMEM:F12 medium (Irvine Scientific), contain-
ing 10% BIT9500 (Stem Cell Technologies), 292 g/mL glu-
tamine (Irvine Scientific), 40 ng/mL FGF, 20 ng/mL EGF, and
20 ng/mL PDGF. For expansion, one-half of this medium was
replaced every other day, and the cultures were passaged every 7
days or when confluent using Nonenzymatic Cell Dissociation
Solution (Sigma). All our GSCs are cultured as previously pub-
lished,27 are able to form spheres when grown on nonadherent
surfaces, and have high surface expression of CD133 in nor-
moxic condition (20%–40%), similar to NSC. In addition, if
the GSCs are grown under conditions favoring glial differentia-
tion, they go on to express GFAP, and if they are grown under
conditions favoring neural differentiation, they go on to express
-3 tubulin, confirming their multipotential nature.
Cell proliferation analysis. Cell proliferation rates were deter-
mined by BrdU incorporation. At 3 or 7 days after TMZ or CIS
treatment, the cells were incubated with BrdU for 24 hours, and
then fixed.Monoclonal anti-BrdU antibody was added, followed by
horseradish peroxidase–conjugated secondary antibody. Tetram-
ethylbenzidine conversion was measured at dual wavelengths of 450
and 540 nm, using a Spectra Max 250 Plate Reader.
Cell death quantification. Necrotic cell death was determined
by propidium iodide staining.28 Cells were collected, incubated with
propidium iodide (5 g/mL), and analyzed by flow cytometry.
Gene expression analysis. RNA was isolated using Trizol
(Invitrogen), and cDNA was synthesized using the SuperScript®
cDNA Synthesis Kit (Invitrogen). Serial PCR reactions (SYBR
Green Master Mix, Qiagen) were conducted to quantify the lev-
els of MGMT, MSH1, MLH2, ABCG2, and the proteasome
subunits  types 5, 6, and 7 (PSMB5, PSMB6, and PSMB7)
using a BioRad C100 Cycler. The levels were normalized to
actin. The specificity of the primers used (table e-2) was con-
firmed for every PCR run by dissociation curve analysis.
Apoptosis analysis. NSCs and GSCs were treated with BTZ
or the vehicle control. Shortly after treatment, 50 M of
caspase-3 inhibitor Z-VAD-FMK was added (Enzyme Systems).
Caspase-3 activity was measured using a Fluorometric Assay Kit
(MBL); 106 cells were harvested 24 hours after treatment with
BTZ (5 nM) and ZVAD (50 M), as indicated, pelleted, and
resuspended in cell lysis buffer. A total of 200 g protein cell
extract was incubated with 200 M DEVD-pNA. Spectropho-
tometric detection of EVD-pNA was performed at 380 nm exci-
tation and 460 nm emission. The results are expressed as a
percentage of control samples. The results are means standard
errors of 6 independent determinations.
Proteasome activity analysis. We measured 20S protea-
some chymotrypsin-like activity using the 20S Proteasome Ac-
tivity Kit (Millipore). Briefly, NSCs and GSCs treated with BTZ
or the vehicle were harvested 4 hours after treatment, pelleted,
and resuspended in cell lysis buffer. A total of 200 g protein cell
extract (supernatant) was incubated with the Proteasome Sub-
strate Suc-LLVY-AMC for 2 hours. The fluorescence was mea-
sured using a 380/460 nm filter set.
Immunocytochemistry. Cells were fixed in 10% buffered
formalin, pretreated in Antigen Retrieval Citra Buffer (Bio-
genex), and, after blockage of with 3% hydrogen peroxide,
avidin-biotin complex immunoperoxidase reactions were per-
formed using an EGFR antibody (Invitrogen). The reactions
were followed by a biotinylated goat-antimouse immunoglobu-
lin G secondary antibody and then an avidin-biotin peroxidase
complex. The chromogen was diaminobenzidine for all reac-
tions. Cells were counterstained with hematoxylin. A section of
normal breast provided the positive controls.
Statistical analysis. Graphs and statistical analyses were pre-
pared using Prism 3.03 (Graph Pad). All values were presented as
mean SEM. Significance was determined with simple paired t
tests or one-way analysis of variance.
RESULTS Human NSCs are more vulnerable to TMZ
in vitro than either high-grade or low-grade GSCs.We
treated 3 NSC cultures and multiple GSC cultures
derived from both low- and high-grade glial tumors
with TMZ with the goal of recreating in vitro the
effects of this first-line treatment for low- and high-
grade glial tumors. We determined that NSCs are
much more sensitive than GSCs to therapeutically
relevant doses of TMZ (with a 50% reduction in the
number of NSCs being present in the cultures 7 days
after as low as 50 M TMZ treatment as compared
with controls (figure 1A). GSCs treatment with sim-
ilar TMZ doses did not have any effect on cell num-
bers. This is a robust observation, confirmed in 3
NSC cultures, as well as in 2 low-grade derived GSC
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cultures and 3 high-grade glioma-derived GSC cul-
tures (figure 1B).
Low-dose but not high-dose TMZ stimulates NSC pro-
liferation, while the GSC proliferation is not affected
by TMZ treatment regardless of the dosage. To inves-
tigate the factors causing the NSC decrease, we
estimated cell proliferation from the rate of BrdU
incorporation. Low-dose TMZ (50 –200 M)
greatly increased the proliferation rate of NSCs at
3 days after the treatment—up to 8 times higher
than the proliferation rate of vehicle-treated cells.
However, higher TMZ doses (500 M) caused a
lesser increase—just 50% compared with the
vehicle-treated cells (figure 1C). The increase in
the proliferation rate was time-limited: 7 days after
TMZ treatment the NSC proliferation rate at its
maximum was just twice as high as the baseline
levels (figure 1D). TMZ treatment had only a
minimal effect on GSCs, with a faint 25% increase in
proliferation observed at day 3 after treatment and es-
sentially baseline levels at day 7 (figure 1, C and D).
TMZ induces cell death in NSCs but not GSCs. A de-
cline in cell number can be secondary either to
increased cell death or decreased proliferation. As
NSC but not GSC proliferation was increased by
TMZ treatment, we decided to determine if TMZ
induced GSC cell death by measuring propidium
iodide incorporation as a marker of necrotic cell
death (figure 2A). Interestingly, 7 days after TMZ
treatment, 25% of the NSCs (SC23) treated with
500 M TMZ and 17% of the NSCs treated with
200 M TMZ were positive for PI staining. PI
incorporation in GSCs was identical for the 2
treatment groups and the control, confirming that
this tumor cell population is resistant to TMZ.
NSC and GSC have high and similar levels of the
TMZ-resistance enzyme MGMT. MGMT is the most
common marker of resistance to TMZ; high MGMT
levels predict poor response to TMZ.8 Therefore, we
measured MGMT expression in 3 NSC cultures, 11
GSC cultures derived from high- and low-grade glio-
Figure 1 Human neural stem/progenitor cells (NSCs) are more sensitive to temozolomide (TMZ) than glioma stem-like cells (GSCs)
(A) In vitro treatment with graded doses of TMZ leads to a decreased number of NSCs (SC27) while minimally affecting GSCs (HuTuP01). (B) Treatment
with 200 M of TMZ kills 50% of the neural stem cells (SC23, SC27, and SC30). The same dose has less toxicity for low-grade (DB01, DB06) and
high-grade (DB05, DB17, HuTu) GSCs. (C) Cellular proliferation of NSC as measured by BrdU incorporation is up to 8 times higher 3 days after the
treatment with low doses of TMZ, but returns to lower levels 7 days after treatment (D). Seven days after TMZ treatment, no significant effects on
proliferation are seen in GSCs.
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mas, and the 2 stable glioma cell lines. The results show
that both NSCs and GSCs have very high and similar
MGMT expression when compared with the stable cell
lines, suggesting that differences in MGMT expression
do not explain the observed differences in the response
to TMZ (figure 2B).
Human NSCs are more vulnerable to CIS in vitro than
GSCs. CIS is very commonly used as a second-line
treatment for glioma and first-line chemotherapy for
childhood CNS malignancies (e.g., medulloblas-
toma). We treated 2 NSC cultures and multiple
GSC cultures with CIS (representative data shown).
Figure 2 Temozolomide (TMZ) induces cell death in neural stem/progenitor cells (NSCs) but not in
glioma stem-like cells (GSCs) by a methyl-guanine methyl transferase (MGMT)–independent
mechanism
(A) Seven days after TMZ treatment, 25% of NSCs (SC23) treated with 500 M TMZ and 17% of NSCs treated with 200
M TMZ were positive for PI staining by flow cytometry, consistent with increased membrane permeability indicative of
necrotic cell death, while GSCs (DB 17) were not affected. (B) NSCs and GSCs have similar gene expressions for the
enzyme controlling resistance to TMZ (MGMT), but much higher expressions than the stable glioma cell lines. The data are
average values of 3 NSC cultures, 11 GSC cultures, and the 2 stable glioma lines.
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CIS had severe effects on NSCs—even a very low
dose of CIS (0.5 M) led to a 50% decrease in the
number of cells in the culture 3 days after the treat-
ment, while doses as high as 5 M effectively eradi-
cated the NSCs (figure 3A). In contrast, low doses of
CIS did not decrease GSCs number, and high doses
(10 M) resulted in less than a 50% decrease,
strongly suggesting that GSCs are resistant to CIS in
our system (figure 3A).
Only very low-dose CIS stimulates NSC proliferation,
while GSC proliferation is not affected by CIS treat-
ment regardless of dosage. Very low-dose CIS treat-
ment (0.1–0.2M) greatly increases NSC proliferation
rate 3 days after the treatment, up to 10 times higher
than the proliferation rate of vehicle-treated cells. How-
ever, low-dose CIS (0.5 M) resulted in only a 50%
increase (figure 3B). The increase in the proliferation
rate was again time-limited: 7 days after the CIS treat-
ment, the NSC proliferation rate returned to baseline
levels (data not shown). Both low- and high-dose CIS
had minimal effect on GSCs, with no measurable in-
crease in proliferation at either day 3 or day 7 after treat-
ment (figure 3B).
NSCs and GSCs have similar gene expression levels for
the mismatch repair enzymes MLH1 and MSH2, but
GSCs have higher levels for the multidrug resistance
protein ABCG2. Sensitivity to CIS is governed by
multiple mechanisms, including the presence of mis-
match repair enzymes (MLH1, MSH2), and the
ability of cells to extrude toxic drugs (ABCG2).
Therefore, we measured MLH1, MSH2, and
ABCG2 expression in 3 NSC cultures, 11 GSC
cultures, and the 2 stable glioma cell lines. NSCs
had higher expression levels of MLH1 and MSH2
than the stable lines (p  0.048), but there was no
difference between GSCs and NSCs (figure 3C).
In contrast, ABCG2 expression levels were 10
times higher in GSCs than in NSCs (p  0.018),
suggesting that the higher resistance of GSCs to
CIS and TMZ, as compared to NSCs, may be due
Figure 3 Neural stem/progenitor cells (NSCs) are more sensitive to cisplatin (CIS) than glioma stem-like cells (GSCs) and display lower
expression levels for ABCG2multidrug resistance gene, but similar levels for the mismatch repair enzyme genes
(A) In vitro treatment with graded doses of CIS leads to a decreased number of NSCs (SC23, SC27) while minimally affecting GSCs (HuTu, DB17). (B)
Cellular proliferation of NSCs, asmeasured by BrdU incorporation, is up to 10 times higher 3 days after the treatment with low doses of CIS, but returns to
lower levels 7 days after treatment (data not shown). (C) NSCs and GSCs have similar gene expressions for the mismatch repair enzymes controlling
resistance to CIS (MSH1, MLH2). (D) NSCs have significantly lower expression of the ABCG2 multidrug resistance gene. The data are average values of 3
NSC cultures, 11 GSC cultures, and the 2 stable glioma lines.
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to greater GSCs ability to extrude chemotherapy
drugs (figure 3D).
NSCs are less sensitive to proteasome inhibition than
GSCs. To examine whether other chemotherapy agents
could eradicate GSCs while preserving NSCs, we tested
the sensitivity of the 2 groups of cells to proteasome
inhibition with BTZ. The results show that GSCs were
very sensitive to BTZ, with doses as low as 0.5 nM
causing more than an 80% reduction in cell numbers 3
days after the treatment (figure 4A). Treatment with
similar low doses of BTZ (0.5–1 nM) stimulated NSC
growth, with cell numbers 2–3 times higher in the treat-
ment group than in the vehicle control, while doses as
high as 5 nM minimally decreased the cell numbers as
compared with the controls. The results were con-
firmed in 2 NSC cultures, 2 low-grade GSC cultures,
and 4 high-grade GSC cultures (figure 4B).
BTZ induces caspase-3 activation in GSCs but not in
NSCs. To examine the causes of observed reduction
in cell numbers and cell death in the GSCs treated
Figure 4 Neural stem/progenitor cells (NSCs) are less sensitive to proteasome inhibition thanglioma stem-like
cells (GSCs) due to higher proteasomeexpression and function and lower caspase-3 activation
(A) In vitro treatment with graded doses of bortezomib (BTZ) kills off the GSCs (HuTuP01) while minimally affecting NSCs
(SC27). (B) Treatment with 5 nM of BTZ killed 75%–90% of the low-grade (DB01, DB06) and high-grade (DB05, DB07,
DB17, HuTu) GSCs. The same dose had less toxicity for NSCs (SC27 and SC30). (C) Caspase-3 activity was measured in
cell extracts, 24 hours after treatment with BTZ (5 nM) and ZVAD (50 M), as indicated. GSCs had high levels of caspase-3
activation after the BTZ treatment, which was reversed by ZVAD addition, while the caspase-3 levels in NSC did not
increase after BTZ treatment. (D) Proteasome activity was measured in cell extracts, at baseline and 4 hours after treat-
ment with BTZ (5 nM). NSCs had higher baseline proteasome levels than GSCs, which remained higher than the GSC levels
after the proteasome inhibition. (E, F) NSCs had significantly higher expression of the proteasome subunits PSMB5,
PSMB6, and PSMB7. The data are average values of 3 NSC cultures, 11 GSC cultures, and the 2 stable glioma lines.
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with BTZ, we measured the activity of caspase-3, a
key enzyme involved in the early stages of apoptosis,
which has been shown to be a major mediator of
proteosome inhibitor toxicity in myeloma cell lines.29
Treatment with 5 nM BTZ resulted in a vigorous
increase in caspase-3 activity, while addition of
caspase-3 inhibitor Z-VAD-FMK effectively de-
creased caspase-3 activity in GSCs (figure 4C). No
caspase-3 induction was seen in the BTZ-treated
NSC, suggesting that NSCs were resistant to protea-
some inhibition.
NSCs have higher proteasome activity and higher lev-
els of PSMB5, PSMB6, and PSMB7 than GSCs. The
cellular factors conferring resistance to BTZ are a
subject of active research, but a number of parame-
ters have been identified, such as increased protea-
some activity in the resistant cells and mutations/
overexpression of proteasome subunits, especially
PSMB5.30 We found that NSCs have 5–7 times
higher proteasome chymotrypsin-like baseline ac-
tivity than the low-grade and high-grade GSCs.
We also discovered that, after BTZ-induced pro-
teasome inhibition, NSCs still retained high levels
of proteosome activity (up to 10 times higher than
that seen in the treated GSCs; figure 4D). We
measured PSMB5, PSMB6, and PSMB7 levels in
3 NSC cultures and 11 GSC cultures derived from
high- and low-grade gliomas. On average, the lev-
els of all 3 subunits were higher in NSCs than in
GSCs, correlating with their high proteasome
functional activity (figure 4, E and F).
EGFR pathway inhibition with ERL preferentially af-
fects GSCs and correlates with EGFR expression. The
EGFR tyrosine kinase inhibitor ERL has been ac-
tively studied as a targeted drug in glioma trials.11,12
In our experiments, treatment with neither low (2
M) nor high (10 M) dose of ERL affected the
number of surviving NSCs, but both decreased the
number of GSCs up to 50% (figure 5A). The re-
sponse to ERL correlated with EGFR expression seen
by immunocytochemistry: GSCs had consistently
high expression of EGFR, while NSCs had only spo-
radic, low-level expression (figure 5B).
DISCUSSION The effects of chemotherapy on NSC
survival depend on the type of chemotherapy studied
(table e-3). The DNA-targeting drugs—namely
TMZ and CIS—severely and preferentially kill
NSCs compared to GSCs. This reduction in the
number of NSCs (CIS can effectively eliminate the
NSCs in our experimental conditions) may explain
the cognitive impairments seen in brain tumor pa-
tients after treatment with these drugs. Unfortu-
nately, neither TMZ nor CIS effectively eliminate
GSCs, an observation which confirms previous stud-
ies suggesting that GSCs are resistant to chemother-
apy20 and could account for the limited prolonged
survival by these treatments.31
In contrast to TMZ and CIS (which target equally
the DNA of cancer and normal cells), the proteasome
inhibitor BTZ is more toxic to GSCs, due to the rela-
tively low functional level of the proteasome in GSCs.
Figure 5 EGFR pathway inhibition with ERL preferentially affects glioma stem-like cells (GSCs) and
correlates with EGFR expression
(A) In vitro treatment with graded doses of ERL led to a decreased number of GSCs (HuTu, DB17) while minimally affecting
neural stem/progenitor cells (NSCs) (SC23, SC27). (B.a) GSCs are overwhelmingly positive for EGFR staining while (B.b)
NSCs have low and sporadic expression (3 NSCs cultures and 5 GSCs cultures tested, representative results shown).
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Even in low concentrations, this drug nearly eliminates
GSCs. Even though BTZ has low penetrance in the
CNS, these data might explain why BTZ is effective in
reducing intracerebral tumor volume in mouse models
of medulloblastoma32 as well as in a phase I study of
recurrent malignant glioma.33
Malignant gliomas are characterized by EGFR
overexpression, which is present in 40% to 60% of
high-grade tumors.34 As ERL also acts at the protein
level, by specifically binding the phosphorylation site
of the receptor and prohibiting EGFR autoactiva-
tion, ERL treatment does not decrease the number of
NSCs, but is able to target (though not very effec-
tively) the GSC. This might occur because NSCs ex-
press surface EGFR only at certain developmental
stages,35 while GSCs express EGFR consistently.
Treatment of brain malignancies with radiation
and chemotherapy frequently results in learning and
memory deficits in survivors.2,3 Radiation reduces
hippocampal neurogenesis,36 resulting in a relatively
diffuse pattern of cognitive impairment, involving
multiple cognitive domains.37 The cognitive effects
of chemotherapeutic agents, as distinct from radia-
tion therapy, are harder to measure, as brain tumor
patients usually receive both, and single or multiple
chemotherapy agents are used at different disease
stages. However, adult patients with primary CNS
lymphoma who have received chemotherapy without
radiation (high-dose methotrexate) still develop a de-
cline in their attention, learning, and memory,37 which
is more pronounced that the reported effects of chemo-
therapy in patients with breast and systemic lym-
phoma.5 The late effects of chemotherapy (even in
absence of radiation) for childhood brain tumors are
prolonged and severe, with many persons exhibiting a
developmental delay.38 Since pediatric patients receive
either cisplatin or carboplatin,38 it is of interest that
these agents result in massive NSC death, which might
explain the patient’s pervasive cognitive loss.
Our data might also explain why the malignant
glioma tumors respond to therapy for a given time,
and then recur. The 5-year follow-up for patients
with newly diagnosed GBM treated with combined
radiation and TMZ shows that fewer then 10% of
the patients survive.39 If GSCs are resistant to TMZ,
then GSCs will continuously repopulate the tumor,
giving rise to daughter cells that may develop TMZ
resistance. As ERL and BTZ seem to be more effec-
tive against the GSCs, these drugs could be targeted
in future clinical trials as maintenance therapy after
TMZ. However, the drug that is most effective
against GSC—BTZ—has limited brain penetrance
and considerable systemic toxicities, so development
of new proteasome inhibitors would be of benefit.
While ERL does not affect NSCs, it only decreases
GSCs survival by 50%. This finding might explain
the clinical data suggesting that ERL has very limited
clinical activity as a single agent.40 Insufficient pen-
etrance in the tumor and possibly the emergence of
more differentiated, precursor-like glioma cells resis-
tant to the EGFR blockage are alternative potential
explanations.
Commonly, patients receive chemotherapy for
many years in combination with other CNS-targeted
treatments. Although the clinical focus should be on
achieving remission (and possibly a cure), it is also im-
portant to attempt to maintain the quality of life of the
survivors by avoiding severe long-term side effects. Us-
ing cancer drugs that have the potential to eradicate the
most aggressive glioma stem-like cells, but preserve neu-
ral stem/progenitor cell populations and brain plastic-
ity, might move us closer to that goal.
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